Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 535 participants.

Also called NCT01522417

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 535 participants (enrolled count) (from the registry)
Sponsor
Medicure (from the registry)
Registry
  • NCT NCT01522417
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01522417. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2018-12 (actual). Results posted on 2021-04-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Acronym
SAVI-PCI
Condition
Acute Coronary Syndromes
Condition
Unstable Angina
Intervention (Drug)
Short Tirofiban
Intervention (Drug)
Eptifibatide
Intervention (Drug)
Long Tirofiban
Lead sponsor
Medicure (class: industry)
Collaborator
SCRI Development Innovations, LLC (class: other)

Record details

Record id
cardio:ct-nct01522417
Content hash
b4cb949dec44d132db3f206b56c945eb28fbe2592365a5229f156f97efe09774